share_log

Oppenheimer Reiterates Outperform on ESSA Pharma, Maintains $17 Price Target

Benzinga ·  Dec 13, 2023 11:36

Oppenheimer analyst Mark Breidenbach reiterates ESSA Pharma (NASDAQ:EPIX) with a Outperform and maintains $17 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment